Pulmatrix Stock Today

PULM Stock  USD 2.00  0.05  2.56%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 79

 
High
 
Low
High
Pulmatrix is selling at 2.00 as of the 23rd of July 2024; that is 2.56 percent increase since the beginning of the trading day. The stock's lowest day price was 1.98. Pulmatrix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Pulmatrix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of June 2024 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
21st of March 2014
Category
Healthcare
Classification
Health Care
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. The company has 3.65 M outstanding shares of which 1.11 K shares are at this time shorted by private and institutional investors with about 0.14 trading days to cover. More on Pulmatrix

Moving against Pulmatrix Stock

  0.51HCM HUTCHMED DRCPairCorr
  0.49ELYM Eliem Therapeutics Upward RallyPairCorr
  0.47A Agilent Technologies Fiscal Year End 18th of November 2024 PairCorr
  0.47ENVB Enveric BiosciencesPairCorr
  0.44WAT WatersPairCorr
  0.41VOR Vor BiopharmaPairCorr

Pulmatrix Stock Highlights

CEO PresidentTeofilo MBA
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.230.2149
Notably Up
Slightly volatile
Total Current Liabilities5.3 M3.9 M
Significantly Up
Slightly volatile
Non Current Liabilities Total12.7 M12.1 M
Sufficiently Up
Slightly volatile
Total Assets30.4 M34 M
Moderately Down
Slightly volatile
Total Current Assets22.2 M20.8 M
Notably Up
Slightly volatile
Debt Levels
Pulmatrix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pulmatrix's financial leverage. It provides some insight into what part of Pulmatrix's total assets is financed by creditors.
Liquidity
Pulmatrix currently holds 8.76 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Pulmatrix has a current ratio of 8.03, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Pulmatrix's use of debt, we should always consider it together with its cash and equity.

Change In Cash

(15.78 Million)
Pulmatrix (PULM) is traded on NASDAQ Exchange in USA. It is located in 99 Hayden Avenue, Lexington, MA, United States, 02421 and employs 22 people. Pulmatrix is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.12 M. Pulmatrix conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 3.65 M outstanding shares of which 1.11 K shares are at this time shorted by private and institutional investors with about 0.14 trading days to cover. Pulmatrix currently holds about 42.91 M in cash with (15.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pulmatrix Probability Of Bankruptcy
Ownership Allocation
Roughly 93.0 pct. of Pulmatrix outstanding shares are held by general public with 7.09 (%) by third-party entities.
Check Pulmatrix Ownership Details

Pulmatrix Stock Institutional Holders

InstituionRecorded OnShares
Morgan Stanley - Brokerage Accounts2024-03-31
25.0
Hanson Mcclain Inc2024-03-31
3.0
Sabby Management Llc2024-03-31
0.0
Renaissance Technologies Corp2024-03-31
114.8 K
Blackrock Inc2024-03-31
54.9 K
Vanguard Group Inc2024-03-31
35.1 K
Geode Capital Management, Llc2024-03-31
24.7 K
State Street Corporation2024-03-31
13.9 K
Tower Research Capital Llc2024-03-31
5.2 K
Td Waterhouse Canada Inc2024-03-31
350
Advisor Group Holdings, Inc.2024-03-31
176
View Pulmatrix Diagnostics

Pulmatrix Historical Income Statement

At this time, Pulmatrix's Net Interest Income is very stable compared to the past year. View More Fundamentals

Pulmatrix Stock Against Markets

Pulmatrix Corporate Management

Additional Information and Resources on Investing in Pulmatrix Stock

When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.42)
Revenue Per Share
3.199
Quarterly Revenue Growth
2.926
Return On Assets
(0.18)
Return On Equity
(0.38)
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.